Metoprolol vs Atenolol

Both metoprolol and atenolol effectively lower blood pressure by reducing heart rate and cardiac output. At standard doses, both achieve blood pressure reductions of approximately 10-15/6-10 mmHg.

For hypertension, both medications are effective, but their role as first-line agents has been questioned by recent evidence. The 2004 ASCOT-BPLA trial showed that atenolol-based therapy was inferior to amlodipine-based therapy for preventing cardiovascular events, leading some guidelines to move beta-blockers from first-line to second-line status for uncomplicated hypertension.

For heart failure with reduced ejection fraction (HFrEF), metoprolol succinate (Toprol-XL) is one of only three beta-blockers with proven mortality benefit (alongside carvedilol and bisoprolol). The MERIT-HF trial ^[1] demonstrated a 34% reduction in all-cause mortality with metoprolol succinate. Atenolol has not been studied in a major heart failure mortality trial and is not recommended for heart failure.

For post-myocardial infarction ^[7], metoprolol has demonstrated mortality reduction in the MIAMI and early beta-blocker trials. Both medications reduce the risk of recurrent MI, but metoprolol has stronger trial evidence.

For rate control in atrial fibrillation, both medications are effective at slowing ventricular rate. There is no strong evidence favoring one over the other for this indication.

A key pharmacological difference is lipophilicity: metoprolol is more lipophilic and crosses the blood-brain barrier more readily, while atenolol is hydrophilic and has less CNS penetration.

Both medications share common beta-blocker side effects including fatigue ^[3][4], cold extremities ^[3][4], dizziness, and bradycardia ^[3][4] (slow heart rate). These are dose-dependent and generally manageable.

Fatigue affects approximately 10-20% of patients with both medications. Metoprolol's greater CNS penetration (due to lipophilicity) may cause more neurological side effects including vivid dreams, sleep disturbances, and depression compared to the more hydrophilic atenolol. Patients experiencing CNS side effects on metoprolol may benefit from switching to atenolol.

Both medications can mask the symptoms of hypoglycemia in diabetic patients, particularly tachycardia. As beta-1 selective agents, they are less likely to affect beta-2 receptors in the lungs and blood vessels than non-selective beta-blockers, but bronchospasm ^[3][4] can still occur at higher doses in patients with asthma or COPD.

Sexual dysfunction (erectile dysfunction, decreased libido) is a recognized side effect of beta-blockers, affecting approximately 5-10% of patients with both medications. This is a class effect rather than specific to either drug.

Both medications should be tapered when discontinuing rather than stopped abruptly, as sudden cessation can cause rebound tachycardia, hypertension, and potentially myocardial ischemia.

Both medications are available as inexpensive generics. Generic atenolol ^[4] costs approximately $4-$8 per month. Generic metoprolol ^[3] tartrate costs approximately $4-$10 per month. Generic metoprolol ^[3] succinate (extended-release) costs approximately $8-$20 per month.

All formulations are included on $4 generic lists ^[3][4] at major pharmacies and covered by essentially all insurance plans. Cost is not a significant differentiating factor between these medications.

Atenolol is taken once daily due to its longer half-life (6-7 hours, but clinical effect extends to 24 hours). Metoprolol tartrate (immediate-release) requires twice-daily dosing. Metoprolol succinate (extended-release) is taken once daily.

For patients who prefer once-daily dosing but need metoprolol specifically (e.g., for heart failure), the succinate extended-release formulation provides this convenience. Neither medication requires routine blood monitoring beyond standard cardiovascular care.

Metoprolol is generally the preferred beta-blocker due to its stronger evidence base for heart failure, post-MI, and cardiovascular mortality reduction. Metoprolol succinate is specifically recommended by heart failure guidelines (ACC/AHA) as one of three evidence-based beta-blockers for HFrEF.

Atenolol may be preferred for patients experiencing CNS side effects (insomnia, vivid dreams, depression) on metoprolol, as its hydrophilic nature results in less brain penetration. It is also reasonable for rate control in atrial fibrillation and as a second-line hypertension agent.

For uncomplicated hypertension without heart failure or prior MI, current guidelines generally recommend ACE inhibitors, ARBs, calcium channel blockers, or thiazide diuretics as first-line options, with beta-blockers reserved for patients with compelling indications.

Both medications should be used cautiously in patients with bradycardia, heart block, severe asthma, or decompensated heart failure. Always consult your healthcare provider for personalized medication selection.